WO2007025977A2 - Anti-tnf alpha producing lactic acid bacteria for the treatment of chronic enterocolitis - Google Patents
Anti-tnf alpha producing lactic acid bacteria for the treatment of chronic enterocolitis Download PDFInfo
- Publication number
- WO2007025977A2 WO2007025977A2 PCT/EP2006/065803 EP2006065803W WO2007025977A2 WO 2007025977 A2 WO2007025977 A2 WO 2007025977A2 EP 2006065803 W EP2006065803 W EP 2006065803W WO 2007025977 A2 WO2007025977 A2 WO 2007025977A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nano3f
- lactic acid
- organism
- micro
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
Definitions
- the present invention relates to a novel treatment of chronic enterocolitis. More specifically, the invention relates to the production of a medicament comprising anti-TNF ⁇ producing lactic acid bacteria, and the use of this medicament in the treatment of chronic enterocolitis.
- IBD Inflammatory bowel disease
- UC ulcerative colitis
- CD Crohn's disease
- IBD diseases appear to result from the unrestrained activation of an inflammatory response in the intestine.
- UC and CD are associated with many symptoms and complications, including growth retardation in children, rectal prolaps, blood in stools, wasting, iron deficiency and anemia.
- UC refers to a chronic, non-specific, inflammatory and ulcerative disease having manifestations primarily in the colonic mucosa. It is frequently characterized by bloody diarrhea, abdominal cramps, blood and mucus in the stoll, malaise, fever, anemia, anorexia, weight loss, leukocytosis, hypoalbuminemia and an elevated erythrocyte sedimentation rate.
- Crohn's disease shares many features in common with ulcerative colitis. Crohn's disease is distinguishable in that lesions tend to be sharply demarcated from adjacent normal bowel, in contrast to the lesions of ulcerative colitis which are fairly diffuse. Additionally, Crohn's disease predominantly afflicts the ileum (ileitis) and the ileum and colon (ileocolitis). In some cases, the colon alone is diseased (granulomatous colitis) and sometimes the entire small bowel is involved. Colon cancer is a known complication of chronic IBD. It is increasingly common in those patients who have IBD for many years. The risk for cancer begins to rise significantly after eight to ten years of IBD, making a fast and efficient treatment of IBD even more important.
- the most commonly used medication to treat IBD includes anti-inflammatory drugs such as corticosteroids and sulicilates such as sulphasalazine and its derivatives.
- anti-inflammatory drugs such as corticosteroids and sulicilates such as sulphasalazine and its derivatives.
- immunosuppressive drugs such as cyclosporine A, mercaptopurin and azathropine are used.
- these medicaments all have serious side effects.
- a recent, successful development in the treatment of IBD consists in the use of compounds, blocking the working of TNF or its receptor. In that respect is the use of TNF antibodies one of the most promising new therapies.
- Tumor necrosis factor ⁇ is a cytokine produced by numerous cell types, including monocytes and macrophages, that was originally identified based on its capacity to induce the necrosis of certain mouse tumors (see e.g., Old, L. (1985) Science 230:630-632). TNF ⁇ has been implicated in the pathophysiology of a variety of other human diseases and disorders, including sepsis, infections, autoimmune diseases, transplant rejection and graft-versus-host disease (see e.g. Moeller, A. et al. (1990) Cytokine2: 162-169; U.S. Patent No. 5,231 ,024 to Moeller et al ; European Patent Publication No.
- Infliximab is a chimeric human-mouse monoclonal antibody of the IgGI K subclass, which specifically targets and irreversibly binds to TNF ⁇ on cell membranes and in blood.
- Single intravenous doses, ranging from 5 to 20 mg/kg of the antibody infliximab resulted in a drastic clinical improvement in active Crohn's disease; it has been launched on the market to treat Crohn's disease in 1998.
- the human monoclonal TNF ⁇ adalimumab was developed, which is currently tested in phase III clinical trials for the treatment of Crohn's.
- Celltech developed Certolizumab pegol, which is a humanized monoclonal pegylated anti- TNF ⁇ antibody, which is currently also tested in phase III clinical trials for the treatment of Crohn's.
- the antibodies are applied in a systemic way, mainly by subcutaneous injection.
- Systemic administration of anti TNF- ⁇ antibody may result in rather serious unwanted effects, including headache, abscess, upper respiratory tract infection and fatigue.
- the unwanted effects associated with systemic delivery could be solved by local delivery on the place of the inflammation.
- a promising system for delivery of biological active compounds in the intestine has been disclosed in WO97/14806 whereby non-invasive gram positive bacteria such as lactic acid bacteria are used to deliver biological active compounds in the gut.
- WO00/23471 discloses that this system can be used to deliver IL-10 to the ileum, whereby this strain can be used to treat IBD.
- WO01/98461 discloses an alternative method for intestinal delivery using yeast.
- a first aspect of the invention is the use of a genetically modified micro-organism, producing an anti TNF- ⁇ antibody, for the preparation of a medicament to treat IBD.
- the term antibody includes, but is not limited to conventional antibodies, chimeric antibodies, single chain antibodies, bifunctional antibodies, bivalent antibodies, diabodies, and camelid antibodies, including antibody fragments such as VHHs; Preferably said antibody is a camelid antibody fragment (VHH; further called nanobody), even more preferably said antibody is a bivalent anti-TNF ⁇ nanobody.
- said genetically modified micro-organisms is a lactic acid bacterium or a yeast. Delivery of biologically active polypeptides into the animal body by lactic acid bacteria has been disclosed in WO9714806; intestinal delivery of peptides by yeast has been described in WO0198461. However, none of these documents mention the delivery of antibodies or nanobodies in the intestine. Production, secretion and delivery in vivo of biological active antibodies or nanobodies is far from evident, as a correct folding and secretion of the antibody is required, and sufficient antibody is required to obtain a neutralizing activity.
- said genetically modified micro-organism is a Lactococcus lactis strain, preferably said genetically a Lactococcus lactis ThyA mutant.
- a specially preferred embodiment is the use of a Lactococcus lactis ThyA mutant, whereby the gene encoding the TNF- ⁇ antibody has been used to disrupt the THYA gene.
- a yeast is be used to deliver the anti TNF- ⁇ antibody.
- said yeast is Saccharomyces cerevisiae, even more preferably said yeast is Saccharomyces cerevisiae subsp. Boulardii.
- IBD includes but is not limited to chronic colitis, ulcerative colitis and Crohn's disease.
- IBD is chronic colitis.
- Another aspect of the invention is a pharmaceutical composition for oral administration, comprising at least one genetically modified anti-TNF ⁇ VHH producing micro-organism.
- said anti-TNF ⁇ VHH is a bivalent antibody.
- the pharmaceutical composition may be liquid, comprising biological active micro-organisms, or it may be solid, comprising dried micro-organisms that can be reactivated when put in a suitable environment. Micro-organisms may be dried by any system, including freeze drying and spray drying.
- Anti-TNF ⁇ VHH producing as used here doesn't imply that the micro-organism is producing the VHH in the pharmaceutical composition, but it means that the micro-organism is viable and can produce the VHH when placed in a suitable environment.
- Micro-organisms may be coated to facilitate the delivery into the gastro-intestinal tract. Such coating are known to the person skilled in that art and was, amongst others, described by Huyghebaert et al. (2005).
- the pharmaceutical composition may further comprise agents to improve the viability of the micro-organisms, such as, but not limited to trehalose.
- the micro-organisms are selected from the group consisting of lactic acid bacteria and yeasts.
- One preferred embodiment is a pharmaceutical composition, whereby the VHH producing micro-organism is a Lactococcus lactis, preferably a ThyA mutant.
- Another preferred embodiment is a pharmaceutical composition, whereby the VHH producing micro-organism is a Lactobacillus sp. preferably a ThyA mutant.
- said ThyA mutants are obtained by gene disruption, using the VHH encoding construct as insert.
- Still another preferred embodiment is a pharmaceutical composition whereby the VHH producing micro-organism is Saccharomyces cerevisiae, preferably S. cerevisiae subspecies boulardii.
- Another aspect of the invention is a method of preventing, treating and/or alleviating at least one disease or disorder of the gastro-intestinal tract, comprising administering to the gastro- intestinal tract an effective amount of an anti-TNF ⁇ VHH producing micro-organism.
- said anti-TNF ⁇ VHH is a bivalent antibody.
- the way of administering can be any way known to the person skilled in the art, and includes, but is not limited to oral and rectal administration.
- the way of administering is oral administration.
- said disease or disorder is a disease or disorder characterized by an imbalance in TNF ⁇ production, and can be treated by TNF ⁇ inactivating compounds such as TNF ⁇ antibodies.
- said disease is an irritable bowel disease, including but not limited to chronic colitis, ulcerative colitis and Crohn's disease. Most preferably, said disease or disorder is chronic colitis.
- said genetically modified micro-organisms is a lactic acid bacterium or a yeast.
- said genetically modified micro-organism is a Lactococcus lactis strain, preferably said genetically a Lactococcus lactis ThyA mutant.
- a specially preferred embodiment is a Lactococcus lactis ThyA mutant, whereby the gene encoding the TNF- ⁇ antibody has been used to disrupt the THYA gene.
- genetically modified micro-organism is a Lactobacillus sp strain, preferably said genetically a Lactobacillus ThyA mutant.
- a specially preferred embodiment is a Lactobacillus ThyA mutant, whereby the gene encoding the TNF- ⁇ antibody has been used to disrupt the THYA gene.
- a yeast is the anti TNF- ⁇ antibody producing microorganism.
- said yeast is Saccharomyces cerevisiae, even more preferably said yeast is Saccharomyces cerevisiae subsp. Boulardii. BRIEF DESCRIPTION OF THE FIGURES
- Fig . 1 Time course of heterologous monovalent and bivalent nanobody NANO3F production by GM L. lactis (LL-NANO3F and LL-NANO3F-3F).
- LL-pTREX1 vector control
- LL-mlL10 L. lactis strain secreting murine interleukin-10.
- A Western blot analysis of proteins secreted from the various strains revealed by anti-Myc Ab. Each lane on the blot represents 250 ⁇ l_ of L. lactis culture supernatant obtained after different periods of growth (2 x 10 7 CFU at time zero).
- E. coli purified monovalent NANO3F (+) and bivalent NANO3F-3F (++) were used as positive control.
- B Concentrations of secreted heterologous Myc-tagged proteins in culture supematants of LL-pTREX1 (O), LL-NANO3F ( ⁇ ), LL-NANO3F-3F (A) and LL-mlL10 (O), as determined by ELISA.
- L. lactis secreted or E. coli purified monovalent and bivalent nanobody NANO3F are able to efficiently neutralize soluble and membrane bound TNF.
- soluble TNF (20 IU/ml) was neutralized by NANO3F and NANO3F-3F in a 16 hour cytotoxicity assay using the WEHI 164 cl 13 cells in the presence of 1 ⁇ g/ml actinomycin D.
- B L. lactis secreted and E. coli purified nanobodies NANO3F and NANO3F-3F were able to inhibit the cytotoxic effects of L929 expressing uncleavable membrane-bound TNF.
- the gray bars represent wells where purified NANO3F or NANO3F-3F was added (total concentration of 250 ng/mL).
- the black bars represent wells where 50 ⁇ l_ of filtered (0.22 ⁇ m) lactococcal supernatant was added.
- the final concentration of LL-NANO3F and LL-NANO3F-3F was 250 ng/ml in each setting.
- FIG. 3 Analysis of morbidity in chronic DSS colitis.
- A-E Representative histology of the middle colon from healthy control mice (A) and mice with chronic DSS colitis either mock- treated (B) or treated with LL-pTREX1 (C), LL-NANO3F-3F (D) or LL-mlL10 (E).
- F Statistical evaluation of the histological score of the middle colon. Bars represent the mean + SEM. White bar represent the healthy control group. Mice with DSS-induced chronic colitis were either mock-treated (hatched bars) or received LL-pTREX1 (black bar), LL-NANO3F-3F (red bar) or LL-mll_10 (gray bar). * * * and * * represent statistical significant differences in comparison with the mock-treated and the vector control groups of P ⁇ 0.001 and P ⁇ 0.01 , respectively.
- Fig . 4 Analysis of morbidity in 20 weeks old 129Sv/Ev IL-10 " ' " mice. Each group received daily for 14 days 2 x 10 9 CFU LL-pTREX1 (vector control), LL-NANO3F-3F or LL-mlL10, except the mock treated group.
- A-D Representative histology of the middle colon from I L- 10 " ' " mice which were mock-treated (A) or treated with LL-pTREX1 (B), LL-NANO3F-3F (C) or LL-mlL10 (D) (hematoxylin and eosin staining).
- Fig. 7 Statistical evaluation of the histological score of the distal colon in mice with chronic DSS colitis. Bars represent the mean + SEM. White bars represent the healthy control group. Mice with DSS-induced chronic colitis received different L. lactis cultures for 28 days whereafter the mice were killed and analyzed immediately. The black bar represents the vector control LL-pTREX1 treated group, the hatched bar those that received LL-NANO3F (L. lactis secreting monovalent 3F), the gray bar those that received LL-NANO3F-3F (L. lactis secreting bivalent 3F-3F-. * * represents a statistical significant difference in comparison with the vector control LL-pTREX1 and the LL-NANO3F treated groups of P ⁇ 0.01.
- Fig. 8 L. lactis secreted monovalent and bivalent Nanobody 3E (anti-human TNF Nanobody) are able to efficiently neutralize soluble human TNF. Soluble human TNF (different concentrations ranging from 30 till 3.3 Ill/ml) was neutralized by 3E and 3E-3E in a 16 hour cytotoxicity assay using L929s cells in the presence of 1 ⁇ g/ml actinomycin D. Cell survival was calculated relative to healthy cells The white bar represents wells where 50 ⁇ L of filtered (0.22 ⁇ m) lactococcal supernatant of the vector control LL-pTREX1 was added.
- Black and gray bars represent wells where 50 ⁇ L of filtered (0.22 ⁇ m) lactococcal supernatant was added; containing L. lactis secreted 3E or 3E-3E, respectively.
- the final concentration of L. lactis secreted 3E or 3E-3E was 250 ng/ml in each setting.
- Bacteria and plasm ids The L. lactis strain MG 1363 was used throughout this study. Bacteria were cultured in GM 17 medium, i.e. M17 (Difco Laboratories, Detroit, Ml) supplemented with 0.5% glucose. Stock suspensions of all strains were stored at -20 0 C in 50% glycerol in GM 17. For intragastric inoculations, stock suspensions were diluted 200-fold in fresh GM 17 and incubated at 30 0 C. They reached a saturation density of 2 x 10 9 colony-forming units (CFU) per ml_ within 16 hours. Bacteria were harvested by centrifugation and concentrated 10-fold in BM9 medium. (Schotte, Steidler et al. 2000). For treatment, each mouse received 100 ⁇ l_ of this suspension daily by intragastric catheter.
- GM 17 medium i.e. M17 (Difco Laboratories, Detroit, Ml) supplemented with 0.5% glucose.
- Stock suspensions of all strains
- Nanobody NANO3F (MW-15 kDa) was isolated.
- the murine TNF specific Nanobody was converted into a bivalent format (coded NANO3F-3F, MW ⁇ 30 kDa) using the 12 aminoterminal residues of the llama lgG2a upper hinge sequence as a spacer.
- MG1363 strains transformed with plasmids carrying the NANO3F or NANO3F-3F coding sequence were designated LL-NANO3F and LL-NANO3F-3F respectively.
- LL-pTREX1 which is MG1363 containing the empty vector pTREXI , served as control.
- Myc-tagged LL-NANO3F and LL-NANO3F-3F were quantified by direct adsorption of crude L. lactis supematants to ELISA plates (Maxisorp F96, Nunc, Rochester, NY) and subsequent detection with a specific mouse mAb against the Myc epitope (Sigma, St. Louis, MO).
- ELISA plates Maxisorp F96, Nunc, Rochester, NY
- a specific mouse mAb against the Myc epitope Sigma, St. Louis, MO
- 3F-3F nanobodies secreted in vivo in colon tissue the entire colon was homogenized in PBS containing 1% BSA and sonicated. The 3F-3F nanobodies were measured in the colon supernatant with the nanobody quantification protocol.
- the plate was washed 5 times and detection was performed by incubation with rabbit-polyclonal-anti-mouse- immunoglobulin-HRP (DAKO, 3, 000-fold diluted) for one hour at RT, and after washing plates were stained with ABTS/H2O2. The OD405nm was measured.
- Anti-soluble and membrane-bound TNF bioassay DAKO, 3, 000-fold diluted
- the inhibitory effect of the NANO3F and NANO3F-3F nanobodies on soluble mTNF (20 IU/mL) was measured in a 16 hour cytotoxicity assay using the mouse fibroblast WEHI 164 cl 13 cells in the presence of 1 ⁇ g/ml actinomycin D, as described. (Espevik and Nissen-Meyer 1986)
- the effect of NANO3F and NANO3F-3F to counteract the cytotoxic effect of membrane-bound TNF was determined on the WEHI 164 cl 13 cells after adding L929 cells, expressing uncleavable, membrane-bound TNF to the cell culture (Decoster et al. 1998).
- MF4/4 macrophages (Desmedt et al. 1998) were incubated with NANO3F-3F (100 ⁇ g/ml). After 1 hour cells were extensively washed (3X) in a sufficient volume of PBS to completely remove all nanobody present in solution. The cells were resuspended and incubated in the presence or absence of LPS for 4 hours. The cells were washed (1X) in PBS and after 4 hours of incubation, the supematans and cells were separated by centrifugation. To measure the soluble TNF release, the WEHI 164 cl 13 cells bioassay was used.
- mice 1 1-week old female BALB/c mice were obtained form Charles River Laboratories (Sulzfeld, Germany). They were housed under SPF conditions. IL-10 knockout mice (129Sv/Ev IL-10 " ' " ) (Kuhn, Lohler et al. 1993) were housed and bred under SPF conditions. The IL-10 ' ' mice were used at 20 weeks of age, at which time chronic colitis had fully developed. All mice were fed standard laboratory feed and tap water ad libitum. The animal studies were approved by the Ethics Committee of the Department for Molecular Biomedical Research, Ghent University (File No. 04/02).
- mice weighing approximately 21 g were induced to chronic colitis by four cycles of administration of 5% (w/v) DSS (40 kDa, Applichem, Darmstadt, Germany) in the drinking water, alternating with 10-day periods of recovery with normal drinking water. (Okayasu, Hatakeyama et al. 1990; Kojouharoff, Hans et al. 1997) Treatment was arbitrarily initiated at day 21 after the fourth cycle of DSS.
- MPO activity in the middle colon tissue was measured as described (Bradley, Priebat et al. 1982). Pure human MPO was used as a standard (Calbiochem, San Diego, CA). Data are expressed as ⁇ g MPO/mm 2 colon tissue. Histological analysis
- the colon was removed, cleaned and opened longitudinally. A segment of 1 cm was taken from the middle part of the colon, embedded in paraffin and sectioned longitudinally. Three sections of 4 ⁇ m were cut at 200 ⁇ m intervals and stained with hematoxylin/eosin. Colon sections were numbered randomly and interpreted semiquantitative ⁇ in a blinded manner by a pathologist. The histological score is the sum of the epithelial damage and lymphoid infiltration, each ranging from 0 to 4 as described (Kojouharoff, Hans et al. 1997).
- Example 1 Anti-TNF- ⁇ VHH production by L. lactis in vitro L. lactis was transformed with the plasmids encoding NANO3F and NANO3F-3F. The production of the antibodies was checked by Western blot and ELISA, using a strain transformed with the empty plasmid pTREX and an IL10 producing strain as reference. The results are shown in Figure 1. NANO3F-3F is produced by L. lactis in similar or higher amounts than NANO3F. The amount produced is significantly higher than for IL10.
- Example 2 LL-NANO3F-3F is bioactive and inhibits both soluble and membrane bound
- NANO3F and NANO3F-3F nanobodies produced by L. lactis on soluble mTNF was measured in a cytotoxicity assay using the mouse fibroblast WEHI 164 cl 13 cells as described by Espevik and Nissen-Meyer (1986).
- E. coli produced NANO3F and NANO3F-3F was used as a positive reference. Both the purified nonobodies as well as the nanobodies produced by L. lactis can neutralize the soluble TNF.
- Example 3 LL-NANO3F-3F effect in vivo on established DSS induced chronic colitis Chronic colitis was induced by DSS as described in materials and methods. Mice were daily treated with 2 10 9 colony forming units (cfu) of either LL-pTREX1 , LL-NANO3F-3F, or LL- mlL10. A mock treatment, and healthy mice ("watercontrol") were used as additional control. The effect of the nano3F-3F nanobody deliverd by L. lactis is comparable to the protection obtained by the in situ produced IL-10 ( Figure 3).
- Example 4 LL-NANO3F-3F effect in vivo on established IL-10 v enterocolitis
- Each group received daily for 14 days 2 x 10 9 CFU of either LL- pTREXI (vector control), LL-NANO3F-3F or LL-mlL10, except the mock treated group.
- the results are summarized in Figure 4. Both the myelperoxidase assay as well as the histological score indicate a significant protection in the LL-NANO3F-3F treated mice.
- mice were treated intragastically over a period of 14 days with LL-NANO3F-3F, using intraperitoneal injection of purified nanobody as control. Anti-Nanobody antibody levels were measured in the mouse seum. The results are shown in Figure 5. While interperitoneal injection of NANO3F-3F is giving a clear immune response, the treatment with LL-NANO3F-3F is not immunogenic and proofs to be safe in that respect.
- Example 6 effect of NANO3F-3F on LPS induction of proinflammatory cytokines
- MF4/4 macrophages (Desmedt et al. 1998) were incubated with NANO3F-3F. The cells were washed and then incubated with LPS. Soluble TNF release was measured using the WEHI 164 cl 13 cell toxicity assay. The results are shown in Figure 6. Pretreatment of the macrophages with NANO3F-3F naobody gives a clear protection against LPS induced soluble TNF production.
- Example 7 bivalent antibodies perform surprisingly better than monovalent antibodies Although bivalent antibodies are larger than monovalent ones, it doesn't affect the production in Lactococcus. The production of bivalent antibodies is at least as good if not better than for monovalent antibodies (Fig. 1 ). However, even more important is the efficacy of the bivalent antibodies. From the in vivo experiments, it is obvious that a monovalent anti-TNF antibody results only in a marginal, non-significant improvement of the histological score, whereas administration of a L. lactis secreting bivalent antibodies results in a significant improvement (Figure 7). Indeed, the neutralizing effect of bivalent antibodies is, for a comparable concentration of protein, more pronounced than that of monovalent antibodies. As long as no complete neutralization is reached, the improvement is more than a factor 2, indicating the effect is not purely due to the double valence of the nanobody ( Figure 8) REFERENCES
- Lactococcus lactis Enzyme Microb Technol 27(10): 761-765. van Asseldonk, M., G. Rutten, et al. (1990). "Cloning of usp45, a gene encoding a secreted protein from Lactococcus lactis subsp. lactis MG1363.” Gene 95(1 ): 155-60. Waterfield, N. R., R. W. Le Page, et al. (1995). "The isolation of lactococcal promoters and their use in investigating bacterial luciferase synthesis in Lactococcus lactis.” Gene
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2006286563A AU2006286563B2 (en) | 2005-08-30 | 2006-08-30 | Anti-TNF alpha producing lactic acid bacteria for the treatment of chronic enterocolitis |
JP2008528509A JP5049973B2 (en) | 2005-08-30 | 2006-08-30 | Anti-TNFα producing lactic acid bacteria for the treatment of chronic enterocolitis |
ES06778386.0T ES2626610T3 (en) | 2005-08-30 | 2006-08-30 | Lactic acid bacteria producing anti-TNF alpha for the treatment of inflammatory bowel disease |
CA2619748A CA2619748C (en) | 2005-08-30 | 2006-08-30 | Novel treatment of chronic enterocolitis |
EP06778386.0A EP1948206B1 (en) | 2005-08-30 | 2006-08-30 | Anti-tnf alpha producing lactic acid bacteria for the treatment of inflammatory bowel disease |
US12/065,335 US9017662B2 (en) | 2005-08-30 | 2006-08-30 | Anti-TNF alpha producing lactic acid bacteria for the treatment of chronic enterocolitis |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05107909 | 2005-08-30 | ||
EP05107909.3 | 2005-08-30 | ||
EP05111654.9 | 2005-12-02 | ||
EP05111654 | 2005-12-02 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2007025977A2 true WO2007025977A2 (en) | 2007-03-08 |
WO2007025977A3 WO2007025977A3 (en) | 2007-06-07 |
WO2007025977A8 WO2007025977A8 (en) | 2008-12-11 |
Family
ID=37335304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/065803 WO2007025977A2 (en) | 2005-08-30 | 2006-08-30 | Anti-tnf alpha producing lactic acid bacteria for the treatment of chronic enterocolitis |
Country Status (7)
Country | Link |
---|---|
US (1) | US9017662B2 (en) |
EP (2) | EP1948206B1 (en) |
JP (1) | JP5049973B2 (en) |
AU (1) | AU2006286563B2 (en) |
CA (2) | CA2619748C (en) |
ES (1) | ES2626610T3 (en) |
WO (1) | WO2007025977A2 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008071751A1 (en) * | 2006-12-14 | 2008-06-19 | Actogenix N.V. | Delivery of binding molecules to induce immunomodulation |
EP2343319A1 (en) | 2010-01-07 | 2011-07-13 | University of Ljubljana | Genetically modified food grade microorganism for treatment of inflammatory bowel disease |
WO2013041672A1 (en) | 2011-09-23 | 2013-03-28 | Actogenix Nv | Modified gram positive bacteria and uses thereof |
WO2013041673A1 (en) | 2011-09-23 | 2013-03-28 | Actogenix Nv | Modified gram positive bacteria and uses thereof |
US8444976B2 (en) | 2008-07-02 | 2013-05-21 | Argen-X B.V. | Antigen binding polypeptides |
EP2725035A1 (en) * | 2007-10-02 | 2014-04-30 | Avaxia Biologics, Inc. | Antibody therapy for use in the digestive tract |
CN104740631A (en) * | 2008-10-29 | 2015-07-01 | 阿布林克斯公司 | Formulations Of Single Domain Antigen Binding Molecules |
US9079955B2 (en) | 2007-10-02 | 2015-07-14 | Avaxia Biologics, Incorporated | Compositions comprising TNF-specific antibodies for oral delivery and methods of use thereof to treat inflammatory bowel disease |
US9745372B2 (en) | 2015-11-12 | 2017-08-29 | Ablynx N.V. | TNF binders |
EP3255149A2 (en) | 2006-05-02 | 2017-12-13 | Intrexon Actobiotics NV | Microbial intestinal delivery of obesity related peptides |
US10633438B2 (en) | 2015-03-31 | 2020-04-28 | Vhsquared Limited | Polypeptides |
US10808014B2 (en) | 2016-09-13 | 2020-10-20 | Intrexon Actobiotics N.V. | Mucoadhesive microorganism |
WO2023277778A1 (en) * | 2021-06-29 | 2023-01-05 | Milmed Unico Ab | Yeast for the treatment of inflammation |
US11623952B2 (en) | 2019-06-21 | 2023-04-11 | Sorriso Pharmaceuticals, Inc. | IL-23 and TNF-alpha binding bi-specific heavy chain polypeptides |
US11667719B2 (en) | 2019-06-21 | 2023-06-06 | Sorriso Pharmaceuticals, Inc. | VHH immunoglobulin chain variable domain that binds to IL-7R and methods of use thereof for treating autoimmune and/or inflammatory diseases |
US11684677B2 (en) | 2016-09-30 | 2023-06-27 | Sorriso Pharmaceuticals, Inc. | Compositions |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015370982B2 (en) | 2014-12-23 | 2019-03-21 | Ilya Pharma Ab | Methods for wound healing |
WO2020114616A1 (en) * | 2018-12-07 | 2020-06-11 | Tillotts Pharma Ag | Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof |
CN110893194B (en) * | 2019-11-20 | 2023-03-14 | 内蒙古伊利实业集团股份有限公司 | New application of bifidobacterium lactis BL-99 in inhibiting intestinal inflammation |
JP2023139384A (en) * | 2022-03-22 | 2023-10-04 | 株式会社HanaVax | Human norovirus gii.2-specific antibody |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3631229A1 (en) | 1986-09-13 | 1988-03-24 | Basf Ag | MONOCLONAL ANTIBODIES AGAINST HUMAN TUMORNESCROSE FACTOR (TNF) AND THEIR USE |
US5919452A (en) * | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
GB9521568D0 (en) * | 1995-10-20 | 1995-12-20 | Lynxvale Ltd | Delivery of biologically active polypeptides |
EP1123314B1 (en) * | 1998-10-20 | 2004-02-18 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Use of a cytokine-producing lactococcus strain to treat colitis |
FR2810337B1 (en) * | 2000-06-20 | 2002-09-13 | Univ Clermont Auvergne | MICROORGANISMS ACTIVE IN THE DIGESTIVE ENVIRONMENT |
MXPA05004955A (en) * | 2002-11-08 | 2005-11-17 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor. |
US20060034845A1 (en) * | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
EP1481681A1 (en) | 2003-05-30 | 2004-12-01 | Claudio De Simone | Lactic acid bacteria combination and compositions thereof |
-
2006
- 2006-08-30 ES ES06778386.0T patent/ES2626610T3/en active Active
- 2006-08-30 CA CA2619748A patent/CA2619748C/en not_active Expired - Fee Related
- 2006-08-30 US US12/065,335 patent/US9017662B2/en active Active
- 2006-08-30 EP EP06778386.0A patent/EP1948206B1/en not_active Not-in-force
- 2006-08-30 EP EP17154791.2A patent/EP3181141A1/en not_active Withdrawn
- 2006-08-30 AU AU2006286563A patent/AU2006286563B2/en not_active Ceased
- 2006-08-30 JP JP2008528509A patent/JP5049973B2/en not_active Expired - Fee Related
- 2006-08-30 WO PCT/EP2006/065803 patent/WO2007025977A2/en active Application Filing
- 2006-08-30 CA CA2925307A patent/CA2925307C/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
See references of EP1948206A2 * |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3255149A2 (en) | 2006-05-02 | 2017-12-13 | Intrexon Actobiotics NV | Microbial intestinal delivery of obesity related peptides |
WO2008071751A1 (en) * | 2006-12-14 | 2008-06-19 | Actogenix N.V. | Delivery of binding molecules to induce immunomodulation |
US9079955B2 (en) | 2007-10-02 | 2015-07-14 | Avaxia Biologics, Incorporated | Compositions comprising TNF-specific antibodies for oral delivery and methods of use thereof to treat inflammatory bowel disease |
EP2725035A1 (en) * | 2007-10-02 | 2014-04-30 | Avaxia Biologics, Inc. | Antibody therapy for use in the digestive tract |
US9346891B2 (en) | 2008-07-02 | 2016-05-24 | Argen-X.N.V. | Antigen binding polypeptides |
US9428580B2 (en) | 2008-07-02 | 2016-08-30 | Argen-X B.V. | Antigen binding polypeptides |
US8444976B2 (en) | 2008-07-02 | 2013-05-21 | Argen-X B.V. | Antigen binding polypeptides |
US8524231B2 (en) | 2008-07-02 | 2013-09-03 | Argen-X B.V. | Antigen binding polypeptides |
US9315576B2 (en) | 2008-07-02 | 2016-04-19 | Argen-X N.V. | Antigen binding polypeptides |
US9221918B2 (en) | 2008-07-02 | 2015-12-29 | Argen-X B.V. | Antigen binding polypeptides |
CN104740631B (en) * | 2008-10-29 | 2019-04-16 | 阿布林克斯公司 | The preparation of single domain antigen-binding molecule |
CN104740631A (en) * | 2008-10-29 | 2015-07-01 | 阿布林克斯公司 | Formulations Of Single Domain Antigen Binding Molecules |
US8754198B2 (en) | 2010-01-07 | 2014-06-17 | University Of Ljubljana | Modified food grade microorganism for treatment of inflammatory bowel disease |
WO2011083080A1 (en) | 2010-01-07 | 2011-07-14 | University Of Ljubljana | Modified food grade microorganism for treatment of inflammatory bowel disease |
EP2343319A1 (en) | 2010-01-07 | 2011-07-13 | University of Ljubljana | Genetically modified food grade microorganism for treatment of inflammatory bowel disease |
US9458467B2 (en) | 2011-09-23 | 2016-10-04 | Intrexon Actobiotics Nv | Modified gram positive bacteria and uses thereof |
US9347036B2 (en) | 2011-09-23 | 2016-05-24 | Intrexon Actobiotics Nv | Modified gram positive bacteria and uses thereof |
US10793825B2 (en) | 2011-09-23 | 2020-10-06 | Intrexon Actobiotics Nv | Modified gram positive bacteria and uses thereof |
WO2013041673A1 (en) | 2011-09-23 | 2013-03-28 | Actogenix Nv | Modified gram positive bacteria and uses thereof |
US9982228B2 (en) | 2011-09-23 | 2018-05-29 | Intrexon Actobiotics Nv | Modified gram positive bacteria and uses thereof |
US10030234B2 (en) | 2011-09-23 | 2018-07-24 | Intrexon Actobiotics Nv | Modified gram positive bacteria and uses thereof |
WO2013041672A1 (en) | 2011-09-23 | 2013-03-28 | Actogenix Nv | Modified gram positive bacteria and uses thereof |
US10519418B2 (en) | 2011-09-23 | 2019-12-31 | Intrexon Actobiotics Nv | Modified gram positive bacteria and uses thereof |
US10633438B2 (en) | 2015-03-31 | 2020-04-28 | Vhsquared Limited | Polypeptides |
US10544211B2 (en) | 2015-11-12 | 2020-01-28 | Ablynx N.V. | TNF binders |
EP3266798A2 (en) | 2015-11-12 | 2018-01-10 | Ablynx NV | Improved tnf binders |
US9745372B2 (en) | 2015-11-12 | 2017-08-29 | Ablynx N.V. | TNF binders |
US10808014B2 (en) | 2016-09-13 | 2020-10-20 | Intrexon Actobiotics N.V. | Mucoadhesive microorganism |
US11384123B2 (en) | 2016-09-13 | 2022-07-12 | Intrexon Actobiotics N.V. | Mucoadhesive microorganism |
US11684677B2 (en) | 2016-09-30 | 2023-06-27 | Sorriso Pharmaceuticals, Inc. | Compositions |
US11623952B2 (en) | 2019-06-21 | 2023-04-11 | Sorriso Pharmaceuticals, Inc. | IL-23 and TNF-alpha binding bi-specific heavy chain polypeptides |
US11667719B2 (en) | 2019-06-21 | 2023-06-06 | Sorriso Pharmaceuticals, Inc. | VHH immunoglobulin chain variable domain that binds to IL-7R and methods of use thereof for treating autoimmune and/or inflammatory diseases |
WO2023277778A1 (en) * | 2021-06-29 | 2023-01-05 | Milmed Unico Ab | Yeast for the treatment of inflammation |
Also Published As
Publication number | Publication date |
---|---|
US9017662B2 (en) | 2015-04-28 |
EP1948206A2 (en) | 2008-07-30 |
US20080274084A1 (en) | 2008-11-06 |
WO2007025977A8 (en) | 2008-12-11 |
EP3181141A1 (en) | 2017-06-21 |
ES2626610T3 (en) | 2017-07-25 |
JP5049973B2 (en) | 2012-10-17 |
EP1948206B1 (en) | 2017-03-01 |
CA2925307C (en) | 2019-12-03 |
WO2007025977A3 (en) | 2007-06-07 |
JP2009506095A (en) | 2009-02-12 |
CA2619748C (en) | 2016-06-14 |
AU2006286563A1 (en) | 2007-03-08 |
CA2925307A1 (en) | 2007-03-08 |
CA2619748A1 (en) | 2007-03-08 |
AU2006286563B2 (en) | 2012-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1948206B1 (en) | Anti-tnf alpha producing lactic acid bacteria for the treatment of inflammatory bowel disease | |
US20100303777A1 (en) | Delivery of binding molecules to induce immunomodulation | |
AU770726B2 (en) | Use of a cytokine-producing lactococcus strain to treat colitis | |
US10238697B2 (en) | Lactococcus lactis producing TSLP or IL-25 and their uses as probiotics and therapeutics | |
EP1931762B1 (en) | Use of recombinant yeast strain producing an anti -inflammatory compound in the manufacture of a medicament to treat colitis | |
JP6843997B2 (en) | Gastrointestinal disease therapeutic drug transfer microorganisms expressing and secreting P8 protein and pharmaceutical compositions for the prevention or treatment of gastrointestinal disease containing the same. | |
Steidler | Microbiological and immunological strategies for treatment of inflammatory bowel disease | |
MX2007004374A (en) | Chimeric protein. | |
Zahirović et al. | Targeting IL-6 by engineered Lactococcus lactis via surface-displayed affibody | |
CN115806615A (en) | Antibody and mesenchymal stem cell exosome preparation method and application of antibody and mesenchymal stem cell exosome in combined treatment of diseases | |
JP2024521419A (en) | Genetically modified Saccharomyces yeast strains as prophylactic and therapeutic agents | |
JP6802924B2 (en) | Pegiocockspentosaseus strain for drug transmission for treating gastrointestinal diseases expressing and secreting cystatin and a pharmacological composition for preventing or treating gastrointestinal diseases containing the same. | |
WO2000006764A1 (en) | Gastrointestinal bacterial antibody factories | |
KR20200110342A (en) | Combination therapy to treat or prevent cancer | |
KR20200110341A (en) | Combination therapy to treat or prevent cancer | |
WO2023126446A1 (en) | Treatment of therapy-induced enteropathy | |
KR20160000949A (en) | RANKL producing recombinant lactic acid bacteria and use thereof | |
Zhang et al. | An M cell-targeting recombinant L. lactis vaccine against four H. pylori adhesins | |
Joosten et al. | BLOCKADE OF ENDOGENOUS INTERLEUKIN-12 RESULTS IN SUPPRESSION OF MURINE STREPTOCOCCAL CELL WALL (SCW) ARTHRITIS BY ENHANCEMENT OF IL-10 AND IL-1Ra. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2619748 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008528509 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12065335 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2006778386 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006286563 Country of ref document: AU Ref document number: 2006778386 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006286563 Country of ref document: AU Date of ref document: 20060830 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006286563 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006778386 Country of ref document: EP |